Trial Design Trips Up Tivozanib, AVEO Pharma Stock Swoons
By Catherine Shaffer
Thursday, February 14, 2013
Stock in AVEO Pharmaceuticals Inc. softened following a clinical trial update released in conjunction with the company's full year 2012 earnings. Trial design may have confounded results for tivozanib, which show overall survival (OS) trends favoring the comparator drug Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG), with OS of 28.8 months for tivozanib and 29.3 months for sorafenib (p = 0. 105).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.